Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $3,678,981 | $3,760,393 | $4,184,347 |
| - Cash | $56,805 | $70,169 | $31,159 |
| + Debt | $1,476 | $2,146 | $10,435 |
| Enterprise Value | $3,623,652 | $3,692,370 | $4,163,623 |
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | -$839 | -$112 | -$15 |
| % Margin | – | – | – |
| EBITDA | -$77,468 | -$34,664 | -$10,352 |
| % Margin | – | – | – |
| Net Income | -$78,307 | -$34,786 | -$10,652 |
| % Margin | – | – | – |
| EPS Diluted | -0.38 | -0.19 | -0.053 |
| % Growth | -100% | -258.5% | – |
| Operating Cash Flow | -$64,828 | -$27,181 | -$3,242 |
| Capital Expenditures | -$2,405 | -$1,636 | -$284 |
| Free Cash Flow | -$67,233 | -$28,817 | -$3,526 |